Rua Bioscience Ltd. 2025 AR2
The report highlights Rua Bioscience's significant progress in FY25, transitioning from strategy to execution with strong revenue growth across Germany, Australia, and New Zealand. The company successfully expanded its product portfolios internationally, including launching its first product in Australia using New Zealand legacy genetics and establishing a sales pipeline in the United Kingdom. Financially, customer revenue rose to $1.51 million, and loss before tax was reduced by 75% to $3.46 million. Additionally, Rua continued its social impact initiatives, expanding its Compassionate Access Programme to support up to 52 patients monthly and awarding scholarships to local youth.
Company: Rua Bioscience Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2025
Type: AR2
Pages: 90
Rua Bioscience Ltd.
The report highlights Rua Bioscience's significant progress in FY25, transitioning from strategy to execution with strong revenue growth across Germany, Australia, and New Zealand. The company successfully expanded its product portfolios internationally, including launching its first product in Australia using New Zealand legacy genetics and establishing a sales pipeline in the United Kingdom. Financially, customer revenue rose to $1.51 million, and loss before tax was reduced by 75% to $3.46 million. Additionally, Rua continued its social impact initiatives, expanding its Compassionate Access Programme to support up to 52 patients monthly and awarding scholarships to local youth.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jul 1, 2024 - Jun 30, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women on Board
Women in Management
Employees